Drug-eluting Microspheres Compared to Conventional Transarterial Chemoembolization as First Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-center Retrospective Cost-utility Analysis
CardioVascular and Interventional Radiology · 2023
DOI: 10.1007/s00270-022-03335-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift CardioVascular and Interventional Radiology, 2023. Verfasst von G Andreozzi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Management, Scuola Superiore Sant'Anna, Piazza Martiri Della Libertà, 33, 56127, Pisa, Italy. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biocompatibles UK Ltd, now a Boston Scientific Company.
Abstract (Originalsprache)
Purpose
To assess the cost-utility of initial treatment with drug-eluting microspheres (DEM) transarterial chemoembolization (TACE) versus conventional (C)-TACE in patients with hepatocellular carcinoma considering the perspective of a Local Healthcare Authority in Italy. Materials and Methods The economic evaluation is based on a retrospective single-center study and individual patients’ data whose details have been previously reported. The impact of initial treatment with DEM-TACE or C-TACE on disease progression, mortality, and direct health costs over a lifetime horizon were simulated and compared in terms of incremental cost-utility ratio expressed as costs per quality adjusted life years (QALY). Costs included direct health costs related to the first chemoembolization procedure and all subsequent follow-up costs associated with health care resources used for disease management. Probabilistic (PSA) sensitivity analysis was used to assess the robustness of the results.
Results
A total of 101 patients in each treatment group were considered. All over the time-horizon median costs were €3,145.14 and €2,158.32 in the DEM-TACE and C-TACE group, respectively ( p < 0.001); while mean costs were € 24,619 and € 17,001, respectively ( p < 0.001). The ICUR was 6,461.86 €/QALY when using median costs derived from the study population as input for the health-economic evaluation and 49,932.15 €/QALY when the mean costs were considered. Results from PSA highlighted that using median costs DEM-TACE was always cost-effective, while using mean costs, it was preferable only 24.7% of times.
Conclusions
The higher prices of DEMs are counterbalanced by the positive impact on QALY.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Management, Scuola Superiore Sant'Anna, Piazza Martiri Della Libertà, 33, 56127, Pisa, Italy.
- Institute of Management, Scuola Superiore Sant'Anna, Piazza Martiri Della Libertà, 33, 56127, Pisa, Italy. valentina.lorenzoni@santannapisa.it.
- Department of Interventional Radiology, Pisa University Hospital, Pisa, Italy.
Förderung
- Biocompatibles UK Ltd, now a Boston Scientific Company
Zitieren
APA
Andreozzi, G., Lorenzoni, V., Bargellini, I., Cioni, R., & Turchetti, G. (2023). Drug-eluting Microspheres Compared to Conventional Transarterial Chemoembolization as First Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-center Retrospective Cost-utility Analysis. CardioVascular and Interventional Radiology. https://doi.org/10.1007/s00270-022-03335-4
Vancouver
Andreozzi G, Lorenzoni V, Bargellini I, Cioni R, Turchetti G. Drug-eluting Microspheres Compared to Conventional Transarterial Chemoembolization as First Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-center Retrospective Cost-utility Analysis. CardioVascular and Interventional Radiology. 2023. doi:10.1007/s00270-022-03335-4
BibTeX
@article{Andreozzi2023,
author = {Andreozzi, G and Lorenzoni, V and Bargellini, I and Cioni, R and Turchetti, G},
title = {Drug-eluting Microspheres Compared to Conventional Transarterial Chemoembolization as First Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-center Retrospective Cost-utility Analysis},
journal = {CardioVascular and Interventional Radiology},
year = {2023},
doi = {10.1007/s00270-022-03335-4}
}
EUVIMED